9/20/2020 1:29:53 PM
AstraZeneca, Merck: LYNPARZ Reduced Risk Of Death By 31% In BRCA1/2 Or ATM Gene Mutations In Phase 3 Profound Trial
9/19/2020 10:46:18 AM
Merck’ KEYTRUDA Reduces Risk Of Distant Metastasis Vs Placebo As Adjuvant Treatment In High-Risk Stage III Melanoma
9/17/2020 8:13:58 AM
Vaccinex Enters Clinical Collaboration Agreement With Merck To Evaluate Pepinemab And KEYTRUDA
9/15/2020 7:01:57 AM
Merck Says Health Canada Has Approved BRENZYS For Four New Indications
9/14/2020 6:52:01 AM
Seattle Genetics, Merck Announce Strategic Oncology Collaborations; Merck To Buy $1 Bln Equity Stake In Seattle Genetics
9/9/2020 8:12:59 AM
Merck Says Two Phase 3 Studies Evaluating V114 Met Primary Immunogenicity Objectives
9/8/2020 8:04:33 AM
Merck: Gefapixant Significantly Decreased Cough Frequency Compared To Placebo At Week 12 And 24
9/2/2020 6:55:25 AM
Merck To Present New Data From Diverse Oncology Development Program
9/2/2020 4:07:56 AM
Highlight Therapeutics Enters Second Phase II Trial Collaboration With Subsidiary Of Merck
9/2/2020 4:05:29 AM
Highlight Therapeutics Enters Second Collaboration With MSD To Evaluate Combination Of BO-112 And KEYTRUDA